Califf, who is described by some as a safe choice for the agency’s top job, headed the FDA during the last year of the Obama administration.
President Joe Biden is expected to announce later this morning that he will nominate Robert Califf, M.D., to be commissioner of the FDA, numerous news outlets are reporting.
Today’s news is not a surprise. Numerous news outlets reported several weeks ago that Califf had emerged as Biden’s top choice. The lack of permanent FDA has been conspicuous by its absence. If confirmed by the Senate, Califf would take over from Janet Woodcock, M.D., who has been acting commissioner since the beginning of the Biden administration.
Related: Why Doesn’t the FDA have a Permanent Commissioner?
This would be Califf’s second stint as FDA commissioner. He was commissioner during the last year of the Obama administration, serving from Feb. 24, 2016 through Jan. 20, 2017.
Politico broke the news that Califf would be nominated this morning just before 9 a.m.
The Wall Street Journal reported that some consumer advocacy groups, such as Public Citizen, have been pushing the administration not to nominate Califf because of his consulting experience with drugmakers.
The Washington Post said FDA experts see him as a “safe choice — an experienced hand who is unlikely to make abrupt changes.” The Post also reported that Califf is a senior adviser to Verily and Google Health.
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Dr. Glaucomflecken the Opening Speaker Today at the 2024 ATS Meeting | 2024 ATS
May 18th 2024William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Read More